DeepBiome is building a drug discovery platform, applying leading research from top institutions to lower the time and cost barrier of drug discovery with its fast and cost-effective next generation technology. The DeepBiome platform combines artificial intelligence and synthetic biology to rapidly identify potential drug candidates which already exist in the human microbiome. DeepBiome already has proof of concept for IBD to a big pharma partner, the development was under 3 months, a fraction of the time to identify candidate compounds using traditional methods.
Enterin is pioneering the medical community’s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease.
eReceivables is a specialty servicer for healthcare receivables and the first company to have created and commercialized a standardized electronic system to process and appeal post-adjudicated disputed healthcare claims.
ROSE-010 is used for the treatment of severe break-through pain associated with Irritable Bowel Syndrome (“IBS”). ROSE-010 has successfully completed two phase 2a trials that showed significant pain relief compared to placebo. IBS is a large indication with few good treatment options for break-through pain episodes. In a meaningful number of cases, patients use opioids to manage pain, which, in addition to the risk of addiction, can cause constipation and exacerbate gastrointestinal issues for IBS sufferers.
Royalty Pharma Select represents an investment in an existing diversified portfolio of leading pharmaceutical and biopharmaceutical products without the risks and infrastructure costs associated with the development and commercialization of such products.
Transparency Life Sciences is the first all-digital clinical development services company. TLS’s approach combines crowdsourcing and mobile health technology to advance drug candidates through clinical trials with unprecedented efficiency and patient and regulatory relevance.
X-Vax Technology is developing a novel vaccine for both the prophylaxis and treatment of herpes simplex virus Type 1 and Type 2 in adults and children. The vaccine candidate was developed in a research laboratory at the Albert Einstein College of Medicine and has been used to characterize the immune response in animals which differs from that of former herpes simplex vaccine candidates. The vaccine confers “sterilizing immunity” with rapid viral clearance and protection from latency in a range of animal models following challenge with a wide range of virulent clinical isolates.